Anticancer Properties of PPAR-Effects on Cellular Metabolism and Inflammation
Figure 1
PPARα interferes with the metabolic pathways in the cancer
cells. In the state of energy deprivation, AMPK activates fatty acid
oxidation through PPARα- and p53-dependent pathways and blocks anabolic
processes, for example, cholesterol biosynthesis. AMPK is a potent inhibitor of
Akt-induced glycolysis. In response to nutrient deficiency, PGC-1α and PPARα upregulate
expression of TRB3,
which inactivates Akt via direct interaction [29]. PPARα promotes fatty acid
β-oxidation as a
transcriptional activator of fatty acid catabolic enzymes and transport
proteins (e.g., ACO, CPT1, UCP2, and UCP3). Simulateneously, PPARα blocks lipid
synthesis by repression of SREBP-1 and -2, ACC, and FAS. FAS inhibition in
various cancer types results in toxic accumulation of malonyl-CoA and
apoptosis. For more details, see the text. Arrowheads represent activation/upregulation, and blunted lines indicate inhibition/downregulation of the
cellular proteins or processes. ACC—acetyl-coA carboxylase; ACO—acyl-coA oxidase;
AMPK—AMP-dependent kinase; CTP-1—carnitine palmitoyltransferase-1; FAS—fatty acid synthase;
PGC-1α—PPARγ coactivator 1α; PUFA—polyunsaturated fatty acids; SREBP—steroid response element
binding protein; TRB3—mammalian homolog of tribbles; UCP2,
UCP3—uncoupling proteins.